ECSP055884A - 3-(3,5 -dioxo-4, 5-dihidro-3h-{1,2,4}triazin-2-il)derivados de benzamidicos como inhibidores del receptor p2x7 para enfermedades inflamatorias - Google Patents

3-(3,5 -dioxo-4, 5-dihidro-3h-{1,2,4}triazin-2-il)derivados de benzamidicos como inhibidores del receptor p2x7 para enfermedades inflamatorias

Info

Publication number
ECSP055884A
ECSP055884A EC2005005884A ECSP055884A ECSP055884A EC SP055884 A ECSP055884 A EC SP055884A EC 2005005884 A EC2005005884 A EC 2005005884A EC SP055884 A ECSP055884 A EC SP055884A EC SP055884 A ECSP055884 A EC SP055884A
Authority
EC
Ecuador
Prior art keywords
receptor
inflammatory diseases
inhibitors
benzamidics
dihidro
Prior art date
Application number
EC2005005884A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Allen Jacob Duplantier
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055884A publication Critical patent/ECSP055884A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)

Abstract

La presente invención proporciona inhibidores benzamídicos del receptor P2X7 de fórmula (ver gráfico). En la que R1-R3 son como se han definido aquí. Los compuestos de la invención son útiles en el tratamiento de trastornos mediados por IL-1, incluidos, sin limitación, enfermedades inflamatorias tales como osteoartritis y artritis reumatoide; alergias, asma, COPD (enfermedad pulmonar obstructiva crónica), cáncer, repercusión o isquemia en accidente cerebrovascular o ataque cardíaco, enfermedades autoinmunes y otros trastornos.
EC2005005884A 2002-12-31 2005-06-21 3-(3,5 -dioxo-4, 5-dihidro-3h-{1,2,4}triazin-2-il)derivados de benzamidicos como inhibidores del receptor p2x7 para enfermedades inflamatorias ECSP055884A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43750502P 2002-12-31 2002-12-31

Publications (1)

Publication Number Publication Date
ECSP055884A true ECSP055884A (es) 2005-09-20

Family

ID=32682427

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005884A ECSP055884A (es) 2002-12-31 2005-06-21 3-(3,5 -dioxo-4, 5-dihidro-3h-{1,2,4}triazin-2-il)derivados de benzamidicos como inhibidores del receptor p2x7 para enfermedades inflamatorias

Country Status (41)

Country Link
US (4) US6974812B2 (es)
EP (1) EP1581232B1 (es)
JP (1) JP4560411B2 (es)
KR (1) KR100689138B1 (es)
CN (1) CN1732006A (es)
AP (1) AP1997A (es)
AR (1) AR042673A1 (es)
AU (1) AU2003285716B2 (es)
BR (1) BR0317803A (es)
CA (1) CA2512193C (es)
CL (1) CL2003002765A1 (es)
CO (1) CO5580749A2 (es)
CR (1) CR7884A (es)
DO (1) DOP2003000790A (es)
EA (1) EA008591B1 (es)
EC (1) ECSP055884A (es)
ES (1) ES2464350T3 (es)
GE (1) GEP20084304B (es)
GT (1) GT200300297A (es)
HR (1) HRP20050609A2 (es)
IL (2) IL168513A (es)
IS (1) IS7840A (es)
MA (1) MA27575A1 (es)
MX (1) MXPA05006749A (es)
MY (1) MY141984A (es)
NI (1) NI200500118A (es)
NL (1) NL1025148C2 (es)
NO (1) NO20053587L (es)
NZ (1) NZ539913A (es)
OA (1) OA12978A (es)
PA (1) PA8591801A1 (es)
PE (1) PE20040802A1 (es)
PL (1) PL378251A1 (es)
PY (1) PY0333692A (es)
RS (1) RS20050490A (es)
TN (1) TNSN05174A1 (es)
TW (1) TWI288133B (es)
UA (1) UA82346C2 (es)
UY (1) UY28153A1 (es)
WO (1) WO2004058270A1 (es)
ZA (1) ZA200503912B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
EP1626962B1 (en) 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
EP1837330B1 (en) * 2003-05-12 2012-10-24 Pfizer Products Inc. Benzamide inhibitors of the P2X7 receptor
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
CA2572118A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
CN1980902A (zh) * 2004-06-29 2007-06-13 辉瑞产品有限公司 通过对羟基保护前体去保护而制备5－4－(2－羟基－丙基)－3，5－二氧代－4，5－二氢－3h－[1，2，4]三嗪－2－基－苯甲酰胺衍生物的方法
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
CA2625940A1 (en) * 2005-08-29 2007-03-08 Irma Bernatchez-Lemaire Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
US20100184802A1 (en) * 2006-03-16 2010-07-22 Kelly Michael G Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
US8093265B2 (en) * 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
AU2009228649B2 (en) 2008-03-25 2014-05-22 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US20140073651A1 (en) 2011-02-22 2014-03-13 Actelion Pharmaceuticals Ltd. Benzamide derivatives as p2x7 receptor antagonists
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
MX2014000894A (es) 2011-07-22 2014-02-27 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7.
EA023752B1 (ru) * 2011-10-03 2016-07-29 Ооо "Эн.Си.Фарм" Фармацевтический состав для инъекций, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, противоишемической активностью (варианты)
TWI576347B (zh) 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物
EA021231B1 (ru) * 2012-02-29 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, обладающий сосудосуживающим, антиконгестивным, противовоспалительным действием (варианты)
EA020041B1 (ru) * 2012-03-11 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, противоишемической активностью (варианты)
EA021266B1 (ru) * 2012-03-14 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, обладающий сосудосуживающим, антиконгестивным, противовоспалительным действием (варианты)
EA020538B1 (ru) * 2012-03-20 2014-11-28 Ооо "Эн.Си.Фарм" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
EA020521B1 (ru) * 2012-03-26 2014-11-28 Ооо "Эн.Си.Фарм" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
EA020539B1 (ru) * 2012-03-26 2014-11-28 Ооо "Эн.Си.Фарм" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
EA201200393A1 (ru) * 2012-03-30 2013-09-30 Анастасия Геннадьевна ЧЕЛЯЕВА Фармацевтический состав, обладающий противомикробным, бактериостатическим действием (варианты)
EA201200446A1 (ru) * 2012-04-06 2013-10-30 Анастасия Геннадьевна ЧЕЛЯЕВА Твердая лекарственная форма, обладающая отхаркивающим, местным обволакивающим и противовоспалительным действием (варианты)
EA020401B1 (ru) * 2012-07-09 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий натрий, кальций, магний, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020060B1 (ru) * 2012-10-01 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020389B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий натрий, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020361B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий магний, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020388B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий натрий, кальций, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020404B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий кальций, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020109B1 (ru) * 2012-10-01 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020403B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий натрий, кальций, магний, железо и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020402B1 (ru) * 2012-10-01 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Фармацевтический состав, содержащий натрий, кальций, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
EA020043B1 (ru) * 2012-10-01 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020129B1 (ru) * 2012-10-01 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020061B1 (ru) * 2012-10-02 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020063B1 (ru) * 2012-10-02 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020062B1 (ru) * 2012-10-02 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020021B1 (ru) * 2012-10-02 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020143B1 (ru) * 2012-10-02 2014-08-29 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая анорексигенным действием (варианты)
EA020162B1 (ru) * 2012-10-04 2014-09-30 Ооо "Эн.Си.Фарм" Твердая лекарственная форма, обладающая желчегонным действием (варианты)
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
EA024401B1 (ru) * 2012-12-28 2016-09-30 Ооо "Биотехсинтез" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP6282017B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
EA201300372A1 (ru) * 2013-04-17 2014-10-30 Ооо "Фармацевтическая Компания "Славянская Аптека" Антиоксидантный фармацевтический состав (варианты)
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
EP3527568A4 (en) 2016-10-17 2020-03-18 Shionogi & Co., Ltd BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFOR

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
AU542544B2 (en) 1980-03-12 1985-02-28 Nippon Kayaku Kabushiki Kaisha Tetrahydrophthalimide derivatives
EP0077938A3 (en) 1981-10-23 1983-08-24 Mitsubishi Kasei Corporation N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition
GR80558B (en) 1983-10-08 1985-02-06 Nippon Kayaku Kk Derivative of pyrazole and use thereof as a herbicide
EP0185731A4 (en) 1984-06-12 1988-11-02 Fmc Corp WEED-KILLING 2-ARYL-1,2,4-TRIAZINE-3,5 (2H, 4H) -DIONE AND THEIR SULFUR ANALOGS.
US4766233A (en) 1984-06-12 1988-08-23 Fmc Corporation Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof
GB8602342D0 (en) * 1986-01-30 1986-03-05 Janssen Pharmaceutica Nv 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones
BR8807217A (pt) 1987-09-23 1989-10-17 Hoffmann La Roche Compostos heterocilicos
US5128351A (en) 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5077409A (en) 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
KR930703259A (ko) 1990-12-17 1993-11-29 알베르투스 빌헬무스 요아네스 쩨스트라텐 살균성 이소퀴놀린 유도체
JP3089621B2 (ja) 1990-12-17 2000-09-18 日産化学工業株式会社 ウラシル誘導体
US5462938A (en) * 1990-12-21 1995-10-31 Annus; Gary D. Arthropodicidal oxadiazinyl, thiadiazinyl and triazinyl carboxanilides
GB9110679D0 (en) 1991-05-17 1991-07-10 Sandoz Ltd Improvements in or relating to organic compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
TW403741B (en) * 1993-10-15 2000-09-01 Takeda Chemical Industries Ltd Triazine derivative, production and use thereof
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
DE4405614A1 (de) 1994-02-22 1995-08-24 Bayer Ag Substituierte Triazolinone
US5686061A (en) 1994-04-11 1997-11-11 The Board Of Regents Of The University Of Texas System Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors
GB9412603D0 (en) 1994-06-23 1994-08-10 Sandoz Ltd Organic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
JPH0959236A (ja) * 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU1335897A (en) 1995-12-21 1997-07-17 Du Pont Merck Pharmaceutical Company, The Isoxazoline, isothiazoline and pyrazoline factor xa inhibitors
DE69706407T2 (de) 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
BR9712000A (pt) * 1996-09-06 1999-08-24 Nippon Kayaku Kk Derivados de acetamida sais dos mesmos composi-Æo farmac-utica inibidores de protease de quimase de desgranula-Æo de mastÄcitos ou de libera-Æo de histamina de mastÄcitos e de ativa-Æo de eosinÄfilo ou de libera-Æo de oxig-nio ativo de eosinÄfilo e processo para produzir os dervados de acetamida
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
DE19701287A1 (de) * 1997-01-16 1998-07-23 Wernicke & Co Gmbh Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben
EP1019375A1 (en) 1997-03-25 2000-07-19 Astra Pharmaceuticals Limited Novel pyridine derivatives and pharmaceutical compositions containing them
WO1998043973A1 (de) 1997-03-27 1998-10-08 Novartis Ag Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US5861950A (en) 1997-07-10 1999-01-19 Particle Measuring Systems, Inc. Particle detection system utilizing an inviscid flow-producing nozzle
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9704272D0 (sv) 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11318492A (ja) 1998-03-09 1999-11-24 Aisin Seiki Co Ltd 蛍光発生性基質を含有する組成物
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
CN1334801A (zh) 1998-12-16 2002-02-06 拜尔公司 作为整联蛋白拮抗剂的新的联苯基和类似联苯基的化合物
TR200102911T2 (tr) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
US6458952B1 (en) * 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
AU5158100A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
CA2387846A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10005284A1 (de) 2000-02-07 2001-08-09 Bayer Ag Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen
GB0006721D0 (en) 2000-03-20 2000-05-10 Mitchell Thomas A Assessment methods and systems
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
EP1626962B1 (en) 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
CA2572118A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
CN1980902A (zh) 2004-06-29 2007-06-13 辉瑞产品有限公司 通过对羟基保护前体去保护而制备5－4－(2－羟基－丙基)－3，5－二氧代－4，5－二氢－3h－[1，2，4]三嗪－2－基－苯甲酰胺衍生物的方法

Also Published As

Publication number Publication date
NL1025148A1 (nl) 2004-07-01
UY28153A1 (es) 2004-07-30
MY141984A (en) 2010-08-16
PY0333692A (es) 2010-05-03
KR20050098848A (ko) 2005-10-12
KR100689138B1 (ko) 2007-03-08
PL378251A1 (pl) 2006-03-20
EA008591B1 (ru) 2007-06-29
NZ539913A (en) 2007-11-30
PE20040802A1 (es) 2004-11-25
IL212241A0 (en) 2011-06-30
DOP2003000790A (es) 2011-10-31
BR0317803A (pt) 2005-11-29
CO5580749A2 (es) 2005-11-30
CN1732006A (zh) 2006-02-08
EP1581232B1 (en) 2014-04-09
US6974812B2 (en) 2005-12-13
TW200413336A (en) 2004-08-01
PA8591801A1 (es) 2004-07-26
MXPA05006749A (es) 2005-09-08
TNSN05174A1 (fr) 2007-05-14
US20060040939A1 (en) 2006-02-23
US7407956B2 (en) 2008-08-05
NL1025148C2 (nl) 2007-09-28
UA82346C2 (xx) 2008-04-10
CA2512193C (en) 2010-09-07
AR042673A1 (es) 2005-06-29
US7176202B2 (en) 2007-02-13
JP2006513206A (ja) 2006-04-20
MA27575A1 (fr) 2005-10-03
RS20050490A (sr) 2007-11-15
GT200300297A (es) 2004-09-21
AP1997A (en) 2009-04-22
IS7840A (is) 2005-05-09
AP2005003350A0 (en) 2005-09-30
NI200500118A (es) 2006-05-19
US20040180894A1 (en) 2004-09-16
OA12978A (en) 2006-10-13
US7671053B2 (en) 2010-03-02
AU2003285716B2 (en) 2010-03-18
ES2464350T3 (es) 2014-06-02
HRP20050609A2 (en) 2006-02-28
IL168513A (en) 2011-06-30
NO20053587L (no) 2005-08-09
WO2004058270A1 (en) 2004-07-15
TWI288133B (en) 2007-10-11
EA200500777A1 (ru) 2005-12-29
CA2512193A1 (en) 2004-07-15
AU2003285716A1 (en) 2004-07-22
US20070281939A1 (en) 2007-12-06
CR7884A (es) 2005-08-05
US20090042886A1 (en) 2009-02-12
JP4560411B2 (ja) 2010-10-13
EP1581232A1 (en) 2005-10-05
CL2003002765A1 (es) 2005-01-07
GEP20084304B (en) 2008-02-11
ZA200503912B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
NI200500118A (es) Derivados de 3-(3,5-dioxo-4,5-dihidro-3h-(1,2,4) triazin-2-il)-benzamida como inhibidores de p2x7 para el tratamiento de enfermedades inflamatorias.
CY1121292T1 (el) Καινοφανη ετεροκυκλικα παραγωγα και χρησεις αυτων
CY1121937T1 (el) Ετεροαρυλικοι αναστολεις της sik
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
CO6551728A2 (es) Amino pirimidinas como inhibidores del syk
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
CY1123760T1 (el) Ανασυνδυασμενοι φορεις aav που εκφραζουν οστεοπροστατευτικα γονιδια, που περιλαμβανουν has2 και λουμπρικινη, χρησιμοι στην θεραπευτικη αγωγη οστεοαρθριτιδας και συναφων παθησεων των αρθρωσεων στα θηλαστικα
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
CY1109194T1 (el) Παραγωγα ν-υδροξυαμιδιου και η χρηση του
EP4744667A2 (en) EFFICIENT AND EVOLVING SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, THEIR MODIFIED DERIVATIVES, THEIR PHOSPHORYL ANALOGUES, THEIR CONJUGATES WITH ADENYLYL DINUCLEOTIDE, AND NEW CRYSTALLINE FORMS THEREOF
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
CA2525437A1 (en) Benzamide inhibitors of the p2x7 receptor
PA8774101A1 (es) Compuesto de pirmidina
AR061568A1 (es) Compuestos
EA201492250A1 (ru) Гетероциклическое соединение
CY1118193T1 (el) Παραγωγα 6,7-διαλκοξυ-κιναζολινης χρησιμα για τη θεραπεια διαταραχων σχετιζομενων με καρκινο
CY1120403T1 (el) Ανταγωνιστες trpm8
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
UY29454A1 (es) Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos
CY1117469T1 (el) Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου
EA202192032A1 (ru) Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение
CU24103B1 (es) Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos
CU23429A3 (es) Derivados de 3-(3,5-dioxo-4,5-dihidro-3h-(1,2,4) triain-2-il) benzamida como inhibidores de p2x7 para el tratamiento de enfermedades inflamatorias
EP3931534A4 (en) BACKGROUND GENERATION OF FTIR SPECTROSCOPY